Abstract

Introduction: Cancer is a devastating disease; however, several therapeutic advances have recently been made, wherein EGFR and its family members have emerged as useful biomarkers and therapeutic targets. EGFR, a transmembrane glycoprotein is a member of the ERBB receptor tyrosine kinase superfamily. EGFR binds to its cognate ligand EGF, which further induces tyrosine phosphorylation and receptor dimerization with other family members leading to enhanced uncontrolled proliferation. Several anti-EGFR therapies such as monoclonal antibodies and tyrosine kinase inhibitors have been developed, which has enabled clinicians to identify and treat specific patient cohorts. Areas covered: This review covers the basic mechanism of EGFR activation and the role of EGFR signaling in cancer progression. Furthermore, current developments made toward targeting the EGFR signaling pathway for the treatment of epithelial cancers and a summary of the various anti-EGFR therapeutic agents that are currently in use are also presented in this review. Expert opinion: EGFR signaling is a part of a complex network that has been the target of effective cancer therapies. However, a further understanding of the system is required to develop an effective anticancer regimen. A combination therapy that comprises an anti-EGFR and a chemotherapeutic/chemopreventive agent will exhibit a multi-pronged approach that can be developed into a highly attractive and specific molecular oriented remedy.

Original languageEnglish (US)
Pages (from-to)15-31
Number of pages17
JournalExpert Opinion on Therapeutic Targets
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Neoplasms
Phosphorylation
Dimerization
Complex networks
Receptor Protein-Tyrosine Kinases
Biomarkers
Epidermal Growth Factor
Protein-Tyrosine Kinases
Tyrosine
Glycoproteins
Therapeutics
Chemical activation
Monoclonal Antibodies
Ligands
Expert Testimony

Keywords

  • Anti-EGFR therapy
  • Cancer
  • EGFR
  • EGFR inhibitors
  • EGFR mutations
  • Signaling
  • Therapeutic targets

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Targeting the EGFR signaling pathway in cancer therapy. / Seshacharyulu, Parthasarathy; Palanimuthu Ponnusamy, Moorthy; Haridas, Dhanya; Jain, Maneesh; Ganti, Apar Kishor P; Batra, Surinder Kumar.

In: Expert Opinion on Therapeutic Targets, Vol. 16, No. 1, 01.01.2012, p. 15-31.

Research output: Contribution to journalReview article

@article{dded39397301437db766e4ac5f7d9548,
title = "Targeting the EGFR signaling pathway in cancer therapy",
abstract = "Introduction: Cancer is a devastating disease; however, several therapeutic advances have recently been made, wherein EGFR and its family members have emerged as useful biomarkers and therapeutic targets. EGFR, a transmembrane glycoprotein is a member of the ERBB receptor tyrosine kinase superfamily. EGFR binds to its cognate ligand EGF, which further induces tyrosine phosphorylation and receptor dimerization with other family members leading to enhanced uncontrolled proliferation. Several anti-EGFR therapies such as monoclonal antibodies and tyrosine kinase inhibitors have been developed, which has enabled clinicians to identify and treat specific patient cohorts. Areas covered: This review covers the basic mechanism of EGFR activation and the role of EGFR signaling in cancer progression. Furthermore, current developments made toward targeting the EGFR signaling pathway for the treatment of epithelial cancers and a summary of the various anti-EGFR therapeutic agents that are currently in use are also presented in this review. Expert opinion: EGFR signaling is a part of a complex network that has been the target of effective cancer therapies. However, a further understanding of the system is required to develop an effective anticancer regimen. A combination therapy that comprises an anti-EGFR and a chemotherapeutic/chemopreventive agent will exhibit a multi-pronged approach that can be developed into a highly attractive and specific molecular oriented remedy.",
keywords = "Anti-EGFR therapy, Cancer, EGFR, EGFR inhibitors, EGFR mutations, Signaling, Therapeutic targets",
author = "Parthasarathy Seshacharyulu and {Palanimuthu Ponnusamy}, Moorthy and Dhanya Haridas and Maneesh Jain and Ganti, {Apar Kishor P} and Batra, {Surinder Kumar}",
year = "2012",
month = "1",
day = "1",
doi = "10.1517/14728222.2011.648617",
language = "English (US)",
volume = "16",
pages = "15--31",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Targeting the EGFR signaling pathway in cancer therapy

AU - Seshacharyulu, Parthasarathy

AU - Palanimuthu Ponnusamy, Moorthy

AU - Haridas, Dhanya

AU - Jain, Maneesh

AU - Ganti, Apar Kishor P

AU - Batra, Surinder Kumar

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Introduction: Cancer is a devastating disease; however, several therapeutic advances have recently been made, wherein EGFR and its family members have emerged as useful biomarkers and therapeutic targets. EGFR, a transmembrane glycoprotein is a member of the ERBB receptor tyrosine kinase superfamily. EGFR binds to its cognate ligand EGF, which further induces tyrosine phosphorylation and receptor dimerization with other family members leading to enhanced uncontrolled proliferation. Several anti-EGFR therapies such as monoclonal antibodies and tyrosine kinase inhibitors have been developed, which has enabled clinicians to identify and treat specific patient cohorts. Areas covered: This review covers the basic mechanism of EGFR activation and the role of EGFR signaling in cancer progression. Furthermore, current developments made toward targeting the EGFR signaling pathway for the treatment of epithelial cancers and a summary of the various anti-EGFR therapeutic agents that are currently in use are also presented in this review. Expert opinion: EGFR signaling is a part of a complex network that has been the target of effective cancer therapies. However, a further understanding of the system is required to develop an effective anticancer regimen. A combination therapy that comprises an anti-EGFR and a chemotherapeutic/chemopreventive agent will exhibit a multi-pronged approach that can be developed into a highly attractive and specific molecular oriented remedy.

AB - Introduction: Cancer is a devastating disease; however, several therapeutic advances have recently been made, wherein EGFR and its family members have emerged as useful biomarkers and therapeutic targets. EGFR, a transmembrane glycoprotein is a member of the ERBB receptor tyrosine kinase superfamily. EGFR binds to its cognate ligand EGF, which further induces tyrosine phosphorylation and receptor dimerization with other family members leading to enhanced uncontrolled proliferation. Several anti-EGFR therapies such as monoclonal antibodies and tyrosine kinase inhibitors have been developed, which has enabled clinicians to identify and treat specific patient cohorts. Areas covered: This review covers the basic mechanism of EGFR activation and the role of EGFR signaling in cancer progression. Furthermore, current developments made toward targeting the EGFR signaling pathway for the treatment of epithelial cancers and a summary of the various anti-EGFR therapeutic agents that are currently in use are also presented in this review. Expert opinion: EGFR signaling is a part of a complex network that has been the target of effective cancer therapies. However, a further understanding of the system is required to develop an effective anticancer regimen. A combination therapy that comprises an anti-EGFR and a chemotherapeutic/chemopreventive agent will exhibit a multi-pronged approach that can be developed into a highly attractive and specific molecular oriented remedy.

KW - Anti-EGFR therapy

KW - Cancer

KW - EGFR

KW - EGFR inhibitors

KW - EGFR mutations

KW - Signaling

KW - Therapeutic targets

UR - http://www.scopus.com/inward/record.url?scp=84855884072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855884072&partnerID=8YFLogxK

U2 - 10.1517/14728222.2011.648617

DO - 10.1517/14728222.2011.648617

M3 - Review article

C2 - 22239438

AN - SCOPUS:84855884072

VL - 16

SP - 15

EP - 31

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 1

ER -